HOLD with tightened parameters: maintain benchmark weight, tighten stop-loss from $92.50 to $94.50, prohibit scaling into position at $95 or below $99.12 gap fill until confirmed technical reversal

• Goodwill went from $91.2 billion to $85.5 billion post-impairment; $85.5 billion remains against $124 billion market cap, not resolved
• $20 billion tech investment conflicts with $76.3 billion total debt and suspended buybacks for deleveraging
• MACD histogram is +0.57 but MACD line remains negative at -1.50 — weakest bullish configuration
• 50 SMA at $100.79 is actively rolling over (from approximately $101.86 on August 14), representing resistance not support
• Institutional sentiment score of 6.3/10 is mildly bullish consistent with HOLD, not a buy signal
• Interest expense climbed 36 percent from $2.29 billion in 2022 to $3.12 billion in 2025 — higher-for-longer rates worsen cash flow drag
• UNH relative value: if UNH is the sector preferred name, capital flows from CVS to UNH, creating relative-performance drag
• Risk-reward to $100.79 target is only $3.56 above $97.23 close versus $4.73 stop — worse than 1:1, not better than 1:1.5
• $92.90 August 25 low represents single test, not validated structural support; requires multiple tests on declining volume
• 10 EMA sits at $95.13 and Bollinger middle band at $94.66; close below $94.50 invalidates bounce thesis
• Do not add capital until stock closes above $99.12 with positive MACD cross and rising volume

→ vs aggressive: Goodwill impairment not a one-time cleanup; $85.5 billion remains with structural pressures from PBM regulatory scrutiny, retail pharmacy reimbursement compression, and elevated Aetna medical loss ratios

→ vs aggressive: $20 billion tech investment is capital allocation question mark, not confidence signal — internal contradiction between deleveraging and technology transformation spending

→ vs aggressive: MACD positive histogram with negative MACD line (-1.50) is weakest bullish configuration; 50 SMA rolling over is overhead supply, not price magnet

→ vs aggressive: Zero Reddit chatter is selection bias, not bullish evidence; institutional sentiment score of 6.3/10 consistent with HOLD only

→ vs aggressive: Higher-for-longer rates invert the narrative — interest expense already up 36 percent to $3.12 billion, creating real cash flow drag

→ vs aggressive: UNH as cheap alternative ignores capital flows: if UNH is preferred name, capital moves from CVS to UNH, not reverse

→ vs aggressive: Risk-reward to $100.79 is worse than 1:1 (only $3.56 upside vs $4.73 downside); asymmetric payoff requires stock to reach $105-$110

→ vs aggressive: Scaling in at $95 is contradicted by own admission that technical structure warrants patience — catching falling knife in broken intermediate-term trend

→ vs aggressive: Single $92.90 test on August 25 is untested pivot, not confirmed support; requires multiple tests over time with bounces building higher lows

→ vs neutral: While endorsing HOLD, conservative framework requires tighter stop at $94.50 (not $92.50) and explicit prohibition on adding below $99.12 until confirmed reversal

Maintain HOLD at benchmark weight; keep stop at $92.50; wait for technical confirmation (close above $99.12 with rising MACD histogram and volume) before revisiting upside sizing; do not scale in on dips below $99.12

• Aggressive analyst incorrectly characterizes positive MACD histogram with negative MACD line (-1.50) as 'textbook accumulation' when it represents weakest bullish configuration
• Risk-reward to 50 SMA ($100.79) is worse than 1:1 ($4.73 down vs $3.56 up to target); asymmetric payoff only materializes at $105-$110
• Aggressive analyst's scaling-in at $95 contradicts their own confirmation framework requiring close above $99.12
• Conservative analyst's stop tightening to $94.50 is too aggressive; $92.50 sits below 8/25 swing low at $92.90 and BB lower band at $91.68
• 50 SMA actively declining from $101.86 to $100.79, acting as overhead resistance not support
• UNH relative-value headwind is real and will weigh on CVS regardless of internal improvement
• Upgrade triggers: close above $99.12 with rising MACD histogram and rising volume
• Downgrade triggers: second goodwill impairment, Q3 2026 FCF below $3.5B, or 200 SMA break at $85.42
• Goodwill impairment ($5.24B, $91.2B to $85.5B) removes immediate overhang but remains structural risk
• Q2 2026 FCF of $5.65B (near double year-ago), raised EPS guide to $7.90-$8.10, and PEG of 0.23 are genuine fundamental signals
• Base-building expected between $92-$100 for several weeks before sustained breakout

→ vs aggressive: MACD interpretation is wrong: positive histogram (+0.57) with negative MACD line (-1.50) is weakest bullish config, not 'textbook accumulation'; no bullish cross has occurred yet (signal at -2.07 vs line at -1.50)

→ vs aggressive: Risk-reward math is cherry-picked: realistic near-term target 50 SMA ($100.79) only $3.56 above current $97.23, yielding worse than 1:1 ratio ($4.73 down vs $3.56 up)

→ vs aggressive: Scaling-in at $95 violates their own confirmation framework requiring close above $99.12 with rising volume; internal contradiction undermines the case

→ vs conservative: Goodwill impairment characterization overstated as 'unresolved'; impairment has been recognized and books written down, removing immediate overhang though structural risk remains

→ vs conservative: Stop tightening to $94.50 is overly aggressive; 10 EMA at $95.13 and BB middle band at $94.66 are noise levels not thesis-invalidation levels; would get stopped on normal volatility during base-building

→ vs conservative: Blanket prohibition on future adds ignores value of upgrade trigger framework; correct to prohibit scaling at $95 but should act when confirmation triggers fire